pancrelipase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	5161	53608-75-6

Description:

Molecule	Description
Synonyms: pancrelipase pancreatin pancreatic extract pancrelipase	A standardized enzyme concentrate containing the pancreatic enzymes, lipase, protease and amylase used in enzyme substitution therapy. Lipase, protease and amylase break down fat, protein, and starches, respectively in the small intestine, thereby promoting digestion. Pancrelipase is used to reduce malabsorption when the pancreas is unable to secrete sufficient amounts of these enzymes. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

pancrelipase
pancreatin
pancreatic extract pancrelipase

A standardized enzyme concentrate containing the pancreatic enzymes, lipase, protease and amylase used in enzyme substitution therapy. Lipase, protease and amylase break down fat, protein, and starches, respectively in the small intestine, thereby promoting digestion. Pancrelipase is used to reduce malabsorption when the pancreas is unable to secrete sufficient amounts of these enzymes.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angina bullosa haemorrhagica	67.40	15.93	12	7082	132	63481796
Needle issue	59.20	15.93	27	7067	10349	63471579
Muscle swelling	52.84	15.93	12	7082	474	63481454
Facial asymmetry	46.82	15.93	12	7082	793	63481135
Vulval disorder	45.87	15.93	12	7082	860	63481068
Early satiety	44.29	15.93	12	7082	984	63480944
Infective pulmonary exacerbation of cystic fibrosis	41.22	15.93	20	7074	8797	63473131
Body temperature decreased	34.90	15.93	24	7070	20295	63461633
Fracture blisters	32.63	15.93	6	7088	80	63481848
Breast pain	32.46	15.93	17	7077	8781	63473147
Frequent bowel movements	32.20	15.93	24	7070	22998	63458930
Infectious thyroiditis	32.07	15.93	5	7089	22	63481906
Liver abscess	31.86	15.93	12	7082	2842	63479086
Pyrexia	29.47	15.93	117	6977	470361	63011567
Pancreatic carcinoma	28.88	15.93	15	7079	7613	63474315
Dehydration	28.47	15.93	61	7033	173293	63308635
Abdominal distension	27.94	15.93	41	7053	86574	63395354
Eosinophilic pneumonia chronic	27.64	15.93	6	7088	192	63481736
Pancreatolithiasis	25.99	15.93	6	7088	255	63481673
Pancreatic carcinoma recurrent	25.68	15.93	5	7089	92	63481836
Drug ineffective	25.53	15.93	49	7045	1044716	62437212
Weight decreased	25.24	15.93	78	7016	276720	63205208
Localised oedema	24.54	15.93	12	7082	5366	63476562
Biliary sepsis	22.57	15.93	7	7087	924	63481004
Pallor	22.42	15.93	22	7072	30546	63451382
Intestinal dilatation	22.02	15.93	8	7086	1714	63480214
Rales	21.81	15.93	15	7079	12682	63469246
Mechanical ileus	21.48	15.93	6	7088	551	63481377
Derailment	21.25	15.93	4	7090	61	63481867
Subileus	20.45	15.93	9	7085	3170	63478758
Thirst	20.45	15.93	15	7079	14026	63467902
Decreased appetite	20.38	15.93	68	7026	250984	63230944
Pancreatic carcinoma metastatic	20.19	15.93	8	7086	2170	63479758
Cystic fibrosis	20.14	15.93	9	7085	3287	63478641
Flatulence	20.09	15.93	22	7072	34680	63447248
Crepitations	20.01	15.93	12	7082	8028	63473900
Chills	19.88	15.93	41	7053	113337	63368591
Abdominal pain upper	18.63	15.93	58	7036	206386	63275542
General physical health deterioration	18.56	15.93	57	7037	201345	63280583
Pancreatitis	18.45	15.93	25	7069	49030	63432898
Mass	18.26	15.93	14	7080	13986	63467942
Joint swelling	18.09	15.93	7	7087	327659	63154269
Blood pressure diastolic increased	17.60	15.93	12	7082	9998	63471930
Underdose	16.93	15.93	18	7076	27438	63454490
Faeces discoloured	16.80	15.93	15	7079	18494	63463434
Blood magnesium decreased	16.78	15.93	13	7081	13185	63468743
Abdominal pain	16.75	15.93	71	7023	293385	63188543
Diarrhoea	16.44	15.93	136	6958	715230	62766698
Haemorrhoids	16.35	15.93	16	7078	22134	63459794
Bile duct stone	16.21	15.93	8	7086	3648	63478280

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	83.52	17.65	35	6286	6766	34943844
General physical health deterioration	61.14	17.65	94	6227	128175	34822435
Enterocolitis infectious	59.75	17.65	19	6302	1676	34948934
Pancreatic carcinoma	47.99	17.65	26	6295	8875	34941735
Abdominal pain upper	37.71	17.65	55	6266	71435	34879175
Toxic optic neuropathy	36.14	17.65	11	6310	839	34949771
Pancreatic carcinoma metastatic	35.65	17.65	15	6306	2925	34947685
Diarrhoea	33.49	17.65	149	6172	389763	34560847
Rash morbilliform	31.68	17.65	14	6307	3073	34947537
Abdominal pain	31.40	17.65	82	6239	163536	34787074
Pancreatic enzyme abnormality	30.11	17.65	6	6315	75	34950535
Steatorrhoea	28.98	17.65	9	6312	734	34949876
Pancreatic neoplasm	27.21	17.65	9	6312	899	34949711
Staphylococcal sepsis	25.45	17.65	18	6303	9826	34940784
Pancreatic disorder	24.83	17.65	10	6311	1744	34948866
Pancreatic failure	24.27	17.65	8	6313	790	34949820
Liver abscess	22.74	17.65	12	6309	3883	34946727
Needle issue	22.55	17.65	14	6307	6151	34944459
Hepatic infection	21.82	17.65	7	6314	635	34949975
Product residue present	20.53	17.65	10	6311	2736	34947874
Cholangitis	20.43	17.65	15	6306	8674	34941936
Adjustment disorder with depressed mood	20.28	17.65	6	6315	415	34950195
Toxic epidermal necrolysis	19.92	17.65	22	6299	21624	34928986
Unmasking of previously unidentified disease	19.39	17.65	7	6314	907	34949703
Liver function test increased	19.25	17.65	18	6303	14547	34936063
Hypopnoea	19.13	17.65	9	6312	2280	34948330
Intercepted product storage error	19.01	17.65	5	6316	224	34950386
Rubber sensitivity	18.95	17.65	5	6316	227	34950383
Hypertransaminasaemia	18.68	17.65	12	6309	5594	34945016
Idiopathic pulmonary fibrosis	18.15	17.65	10	6311	3524	34947086
Biliary tract infection	17.67	17.65	6	6315	649	34949961

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	105.40	14.94	48	12700	12803	79718837
Pancreatic carcinoma	81.71	14.94	41	12707	13536	79718104
Needle issue	77.29	14.94	39	12709	13029	79718611
General physical health deterioration	72.32	14.94	145	12603	275093	79456547
Pancreatic carcinoma metastatic	50.75	14.94	20	12728	3733	79727907
Angina bullosa haemorrhagica	46.50	14.94	10	12738	211	79731429
Liver abscess	44.61	14.94	21	12727	6033	79725607
Body temperature decreased	43.21	14.94	38	12710	32107	79699533
Abdominal pain upper	41.86	14.94	103	12645	223716	79507924
Diarrhoea	40.25	14.94	259	12489	880230	78851410
Toxic optic neuropathy	38.30	14.94	12	12736	1141	79730499
Pancreatic failure	38.11	14.94	13	12735	1615	79730025
Muscle swelling	37.54	14.94	11	12737	834	79730806
Vulval disorder	36.28	14.94	10	12738	608	79731032
Drug ineffective	35.58	14.94	75	12673	1080838	78650802
Facial asymmetry	33.41	14.94	10	12738	816	79730824
Weight decreased	33.02	14.94	128	12620	355070	79376570
Rash morbilliform	32.45	14.94	17	12731	6133	79725507
Pancreatic disorder	32.03	14.94	14	12734	3388	79728252
Pyrexia	31.77	14.94	201	12547	678508	79053132
Pancreatic neoplasm	31.50	14.94	11	12737	1465	79730175
Abdominal distension	31.30	14.94	63	12685	119587	79612053
Abdominal pain	31.16	14.94	134	12614	389435	79342205
Biliary sepsis	30.52	14.94	11	12737	1606	79730034
Fracture blisters	30.49	14.94	6	12742	80	79731560
Cholangitis	30.00	14.94	21	12727	12755	79718885
Staphylococcal sepsis	29.54	14.94	22	12726	14704	79716936
Biliary tract infection	28.31	14.94	10	12738	1378	79730262
Bile duct stone	28.21	14.94	15	12733	5574	79726066
Early satiety	27.96	14.94	10	12738	1429	79730211
Pancreatic enzyme abnormality	27.75	14.94	6	12742	130	79731510
Pancreatolithiasis	27.44	14.94	7	12741	315	79731325
Pancreatic carcinoma recurrent	25.84	14.94	6	12742	181	79731459
Malignant neoplasm progression	25.84	14.94	63	12685	135927	79595713
Toxicity to various agents	25.72	14.94	18	12730	421522	79310118
Enterocolitis infectious	24.41	14.94	11	12737	2858	79728782
Steatorrhoea	24.11	14.94	8	12740	913	79730727
Pancreatitis chronic	23.78	14.94	12	12736	4007	79727633
Subileus	22.57	14.94	13	12735	5641	79725999
Infectious thyroiditis	22.48	14.94	5	12743	124	79731516
Frequent bowel movements	21.40	14.94	25	12723	29514	79702126
Cystic fibrosis	21.26	14.94	11	12737	3869	79727771
Chills	21.20	14.94	65	12683	160169	79571471
Product use issue	21.07	14.94	4	12744	209818	79521822
Breast pain	20.37	14.94	14	12734	8251	79723389
Decreased appetite	20.24	14.94	108	12640	342310	79389330
Mechanical ileus	20.20	14.94	7	12741	912	79730728
Eosinophilic pneumonia chronic	19.78	14.94	6	12742	512	79731128
Joint swelling	19.42	14.94	11	12737	288635	79443005
Hepatic infection	19.35	14.94	7	12741	1033	79730607
Product residue present	19.30	14.94	10	12738	3526	79728114
Pulmonary function test decreased	18.98	14.94	13	12735	7624	79724016
Intercepted product storage error	18.94	14.94	5	12743	258	79731382
Derailment	18.80	14.94	4	12744	80	79731560
Odynophagia	18.53	14.94	15	12733	11312	79720328
Hypertransaminasaemia	17.86	14.94	15	12733	11909	79719731
Pallor	17.66	14.94	30	12718	50032	79681608
Idiopathic pulmonary fibrosis	17.62	14.94	10	12738	4218	79727422
Pancreatic pseudocyst	17.34	14.94	7	12741	1390	79730250
Flatulence	16.96	14.94	27	12721	42697	79688943
Dehydration	16.55	14.94	81	12667	248106	79483534
Hypokalaemia	15.96	14.94	55	12693	143985	79587655
Intestinal dilatation	15.79	14.94	8	12740	2692	79728948
Pancreatitis	15.47	14.94	34	12714	68541	79663099
Hydrocholecystis	15.45	14.94	5	12743	528	79731112
Vomiting	15.26	14.94	168	12580	665660	79065980

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D005765	Gastrointestinal Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Exocrine pancreatic insufficiency	indication	47367009	DOID:13316

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
FQ3DRG0N5K	UNII
4018109	VANDF
4018414	VANDF
C0770343	UMLSCUI
CHEMBL2108074	ChEMBL_ID
DB00085	DRUGBANK_ID
CHEMBL2108073	ChEMBL_ID
D020799	MESH_DESCRIPTOR_UI
235379	RXNORM
41216	MMSL
5227	MMSL
5615	MMSL
d01002	MMSL
d01003	MMSL
001234	NDDF
001235	NDDF
12236006	SNOMEDCT_US
387049005	SNOMEDCT_US
387265002	SNOMEDCT_US
48647005	SNOMEDCT_US
D010194	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FESTAL PLUS	HUMAN OTC DRUG LABEL	3	72689-0010	TABLET	315 mg	ORAL	unapproved drug other	6 sections
Stozyme	HUMAN OTC DRUG LABEL	4	72850-0004	TABLET	36.46 1	ORAL	unapproved drug other	7 sections